FI946140A0 - Diazabicykliska neurokininantagonister - Google Patents

Diazabicykliska neurokininantagonister

Info

Publication number
FI946140A0
FI946140A0 FI946140A FI946140A FI946140A0 FI 946140 A0 FI946140 A0 FI 946140A0 FI 946140 A FI946140 A FI 946140A FI 946140 A FI946140 A FI 946140A FI 946140 A0 FI946140 A0 FI 946140A0
Authority
FI
Finland
Prior art keywords
diazabicyclic
neurokinin antagonists
compounds
formula
disorders
Prior art date
Application number
FI946140A
Other languages
English (en)
Finnish (fi)
Other versions
FI946140A (sv
FI108296B (sv
Inventor
Jr Harry R Howard
Kevin D Shenk
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI946140A0 publication Critical patent/FI946140A0/sv
Publication of FI946140A publication Critical patent/FI946140A/sv
Application granted granted Critical
Publication of FI108296B publication Critical patent/FI108296B/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI946140A 1993-12-29 1994-12-28 Förfarande för framställning av terapeutiskt aktiva 1,6-diazabicyklo[3.2.1]oktan- och 1,4-diazabicyklo[3.3.1]nonanderivat FI108296B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17503493A 1993-12-29 1993-12-29
US17503493 1993-12-29

Publications (3)

Publication Number Publication Date
FI946140A0 true FI946140A0 (sv) 1994-12-28
FI946140A FI946140A (sv) 1995-06-30
FI108296B FI108296B (sv) 2001-12-31

Family

ID=22638565

Family Applications (1)

Application Number Title Priority Date Filing Date
FI946140A FI108296B (sv) 1993-12-29 1994-12-28 Förfarande för framställning av terapeutiskt aktiva 1,6-diazabicyklo[3.2.1]oktan- och 1,4-diazabicyklo[3.3.1]nonanderivat

Country Status (26)

Country Link
US (2) US5854239A (sv)
EP (1) EP0737194B1 (sv)
JP (1) JP2895630B2 (sv)
KR (1) KR100197454B1 (sv)
CN (1) CN1046515C (sv)
AT (1) ATE177099T1 (sv)
AU (1) AU699465B2 (sv)
BR (1) BR9408450A (sv)
CA (1) CA2180263C (sv)
CO (1) CO4230019A1 (sv)
CZ (1) CZ282567B6 (sv)
DE (1) DE69416869T2 (sv)
DK (1) DK0737194T3 (sv)
ES (1) ES2127946T3 (sv)
FI (1) FI108296B (sv)
GR (1) GR3029853T3 (sv)
HU (1) HUT74682A (sv)
IL (1) IL112118A (sv)
NO (1) NO305600B1 (sv)
NZ (1) NZ274915A (sv)
PE (1) PE49395A1 (sv)
PL (1) PL179435B1 (sv)
RU (1) RU2124014C1 (sv)
TW (1) TW369526B (sv)
WO (1) WO1995018129A1 (sv)
ZA (1) ZA9410339B (sv)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL179435B1 (pl) * 1993-12-29 2000-09-29 Pfizer Diazabicykliczni antagonisci neurokininy PL
FR2786770B1 (fr) * 1998-12-04 2001-01-19 Synthelabo Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
DE60129562T2 (de) * 2000-06-12 2008-04-17 The University Of Rochester Methode zur Behandlung von Hitzewallungen durch Verwendung eines Tachykinin-Rezeptor-Antagonisten
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
SE0003795D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7541357B2 (en) 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US20060281670A1 (en) * 2005-06-10 2006-12-14 Wisconsin Alumni Research Foundation (Warf) Compositions and methods for modulating angiogenesis
GEP20125566B (en) 2005-07-15 2012-07-10 Amr Technology Inc Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
TWI404532B (zh) * 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
UA101966C2 (en) 2008-01-18 2013-05-27 Мерк Шарп Енд Доме Корп. Beta-lactamase inhibitors
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
PE20120373A1 (es) 2009-05-12 2012-05-17 Albany Molecular Res Inc 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション p53活性を増大する置換ピペリジン及びその使用
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
DK2606134T3 (da) 2010-08-17 2019-07-22 Sirna Therapeutics Inc RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
CN103328476B (zh) * 2010-12-22 2016-12-28 明治制果药业株式会社 光学活性二氮杂环辛烷衍生物及其制备方法
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
JP5666743B2 (ja) * 2011-08-27 2015-02-12 ウォックハート リミテッド 1,6−ジアザビシクロ[3,2,1]オクタン−7−オン誘導体および細菌感染の処置におけるそれらの使用
WO2013030735A1 (en) * 2011-08-30 2013-03-07 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections
AU2012310136B2 (en) * 2011-09-13 2016-07-07 Wockhardt Limited Nitrogen containing compounds and their use
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
MX366948B (es) * 2012-05-30 2019-07-30 Meiji Seika Pharma Co Ltd Nuevo inhibidor de beta-lactamasa y proceso para prepararlo.
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
RU2627700C2 (ru) * 2013-03-08 2017-08-10 Вокхардт Лимитед Способ получения (2s,5r)-7-оксо-6-сульфоокси-2-[((3r)-пиперидин-3-карбонил)-гидразинокарбонил]-1,6-диазабицикло[3.2.1]октана
JP6285968B2 (ja) * 2013-03-08 2018-02-28 ウォックハート リミテッド (2s,5r)−6−ベンジルオキシ−7−オキソ−1,6−ジアザ−ビシクロ[3.2.1]オクタン−2−カルボン酸のナトリウム塩およびその調製
US9556174B2 (en) * 2013-03-08 2017-01-31 Wockhardt Limited (2S, 5R)-sulfuric acid mono-{[(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester
US9624222B2 (en) * 2013-03-08 2017-04-18 Wockhardt Limited Process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2-[((3R)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octance
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
HUE049027T2 (hu) * 2013-09-24 2020-08-28 Meiji Seika Pharma Co Ltd Diazabiciklooktán-származékok és intermedierek elõállítási eljárása
RS58429B1 (sr) 2014-11-17 2019-04-30 Entasis Therapeutics Ltd Kombinovana terapija za lečenje rezistentnih bakterijskih infekcija
JP2018510198A (ja) * 2015-04-03 2018-04-12 ミュタビリスMutabilis 複素環式化合物及びそれらの細菌感染症の予防または治療のための使用
CN114591223A (zh) 2016-09-16 2022-06-07 恩塔西斯治疗有限公司 β-内酰胺酶抑制剂化合物
TWI791018B (zh) 2017-05-08 2023-02-01 美商安特西醫療公司 治療細菌感染之化合物及方法
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
CN108610313B (zh) * 2018-06-08 2022-03-04 三峡大学 一种酶抑制剂及其应用
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3494923A (en) * 1965-05-28 1970-02-10 Sterling Drug Inc 1,2,3,4,5,8-hexahydro-1,5-methanobenzo (f)(1,4)diazocine
DK0573522T3 (da) * 1991-03-01 1995-03-06 Pfizer 1-Azabicyclo(3,2,2)nonan-3-aminderivater
PL179435B1 (pl) * 1993-12-29 2000-09-29 Pfizer Diazabicykliczni antagonisci neurokininy PL

Also Published As

Publication number Publication date
IL112118A0 (en) 1995-03-15
PE49395A1 (es) 1996-01-06
EP0737194B1 (en) 1999-03-03
CZ188696A3 (en) 1996-10-16
BR9408450A (pt) 1997-08-05
CN1046515C (zh) 1999-11-17
KR100197454B1 (ko) 1999-06-15
CO4230019A1 (es) 1995-10-19
CA2180263C (en) 2000-05-16
PL315193A1 (en) 1996-10-14
NO962742D0 (no) 1996-06-28
CZ282567B6 (cs) 1997-08-13
DE69416869T2 (de) 1999-07-01
HUT74682A (en) 1997-01-28
FI946140A (sv) 1995-06-30
EP0737194A1 (en) 1996-10-16
NO962742L (no) 1996-06-28
HU9601790D0 (en) 1996-09-30
NO305600B1 (no) 1999-06-28
US5854239A (en) 1998-12-29
DE69416869D1 (de) 1999-04-08
GR3029853T3 (en) 1999-07-30
WO1995018129A1 (en) 1995-07-06
AU699465B2 (en) 1998-12-03
JPH09500904A (ja) 1997-01-28
IL112118A (en) 1998-10-30
AU8002194A (en) 1995-07-17
US6110919A (en) 2000-08-29
DK0737194T3 (da) 1999-09-27
CN1139434A (zh) 1997-01-01
JP2895630B2 (ja) 1999-05-24
TW369526B (en) 1999-09-11
ATE177099T1 (de) 1999-03-15
RU2124014C1 (ru) 1998-12-27
ES2127946T3 (es) 1999-05-01
PL179435B1 (pl) 2000-09-29
FI108296B (sv) 2001-12-31
NZ274915A (en) 1997-11-24
ZA9410339B (en) 1996-06-28

Similar Documents

Publication Publication Date Title
DK0737194T3 (da) Diazabicykliske neurokininantagonister
FI935585A0 (fi) Pyrrolopyrimidiner
FI941022A0 (sv) Spirocykliska piperidinderivat
FI941212A0 (sv) Fusionerade tricykliska, svavelinnehållande heterocykliska föreningar
CA2150123A1 (en) Aminomethylene substituted non-aromatic heterocycles
DK0772603T3 (da) Substituerede pyrimidinforbindelser og deres anvendelse
DK0765320T3 (da) Benzimidazolonderivater med central dopaminerg aktivitet
SE9702564D0 (sv) New compounds
PT775118E (pt) Derivados de benzimidazole com actividade dopaminergica
TR200101476T2 (tr) N-ikameli azabisikloaklan türevlerinin merkezi sinir sistemi bozukluklarının tedavisinde kullanılması

Legal Events

Date Code Title Description
MA Patent expired